Viridian Therapeutics, Inc. (0K1R.L) LSE
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Viridian Therapeutics, Inc.
Address
221 Crescent Street
Waltham, MA 02453
United States of America (the)
Phone
617 272 4600
Sector
Healthcare
Industry
Biotechnology
Employees
252
First IPO Date
January 29, 2018
Key Executives
| Name | Title | Pay | Year Born |
| Stephen F. Mahoney | Chief Executive Officer, President & Director | 1.34M | 1971 |
| Seth Harmon | Chief Financial Officer | 785,651 | 1981 |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | 819,951 | 1973 |
| Radhika Tripuraneni | Chief Medical Officer | 840,686 | 1980 |
| Thomas W. Beetham | Chief Operating Officer | 972,976 | 1970 |
| Melissa Manno | Chief Human Resources Officer | 0 | N/A |
| Vahe Bedian | Co-Founder & Scientific Advisor | 0 | N/A |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | 0 | N/A |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | 0 | 1940 |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | 0 | 1945 |
Description
Viridian Therapeutics, Inc. operates as a biotechnology firm dedicated to developing treatments for patients grappling with serious medical conditions. Central to their pipeline are several investigational therapies targeting IGF-1R. This includes VRDN-001, a humanized monoclonal antibody currently advancing through Phase 1/2 clinical trials as a potential therapy for thyroid eye disease (TED). Additionally, VRDN-002, another IGF-1R antibody, is undergoing Phase 1 clinical evaluation. Their portfolio also features VRDN-003, a therapeutic antibody engineered to target IGF-1R, also intended for TED treatment. Known previously as Miragen Therapeutics, Inc., the company officially adopted the name Viridian Therapeutics, Inc. in January 2021. Founded in 2006, Viridian Therapeutics maintains its corporate headquarters in Waltham, Massachusetts.
